. . . . . . . . . "\"Rizatriptan benzoate tablets are contraindicated in patients with: * Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see Warnings and Precautions ( 5.1 * Coronary artery vasospasm including Prinzmetal's angina [see Warnings and Precautions ( 5.1 * History of stroke or transient ischemic attack (TIA) [see Warnings and Precautions ( 5.4 * Peripheral vascular disease (PVD) [see Warnings and Precautions ( 5.5 * Ischemic bowel disease [see Warnings and Precautions ( 5.5 * Uncontrolled hypertension [see Warnings and Precautions ( 5.8 * Recent use (i.e., within 24 hours) of another 5-HT 1 [see Drug Interactions ( 7.2 7.3 * Hemiplegic or basilar migraine. * Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor [see Drug Interactions ( 7.5 12.3 * Hypersensitivity to rizatriptan benzoate tablets or rizatriptan benzoate orally disintegrating tablets (angioedema and anaphylaxis seen) [see Adverse Reactions ( 6.2 * History of ischemic heart disease or coronary artery vasospasm ( 4 * History of stroke or transient ischemic attack ( 4 * Peripheral vascular disease ( 4 * Ischemic bowel disease ( 4 * Uncontrolled hypertension ( 4 * Recent (within 24 hours) use of another 5-HT 1 4 * Hemiplegic or basilar migraine ( 4 * MAO-A inhibitor used in the past 2 weeks ( 4 * Hypersensitivity to rizatriptan benzoate( 4\"" . . . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" . "hpr6RALm/XiZ728FefzqvgvfH47zAddRv2y/RB5akx6Io8Bs21nKstq9xcPjflUbDg8KkCdRtsDSbM8ry733FIjrCUtQN5nsY9N5i0B/1HW4PgRADCyPdyvD97FIMhoSFuhCkwvt+1dZ/fUDPGvIAQSh0AbocjYd2iMXgoIksvA=" . . "2021-08-23T18:05:19.392+02:00"^^ . . . . .